



Clinical trial results:

A Randomized, Observer-blind, Placebo-controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26. ZEBOV and MVA-BN-Filo in Healthy Adults in Europe

Summary

| | |
|--------------------------|-----------------|
| EudraCT number | 2015-000596-27 |
| Trial protocol | GB |
| Global end of trial date | 19 January 2018 |

Results information

| | |
|--------------------------------|-------------------|
| Result version number | v2 (current) |
| This version publication date | 25 September 2019 |
| First version publication date | 03 February 2019 |
| Version creation reason | |

Trial information

Trial identification

| | |
|-----------------------|-----------------|
| Sponsor protocol code | VAC52150EBL2001 |
|-----------------------|-----------------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT02416453 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|--|
| Sponsor organisation name | Janssen Vaccines & Prevention B.V. |
| Sponsor organisation address | Archimedesweg 4-6, Leiden, Netherlands, 2333 CN |
| Public contact | Clinical Registry Group, Janssen Vaccines & Prevention B.V., ClinicalTrialsEU@its.jnj.com |
| Scientific contact | Clinical Registry Group, Janssen Vaccines & Prevention B.V., ClinicalTrialsEU@its.jnj.com |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 23 November 2018 |
| Is this the analysis of the primary completion data? | No |

| | |
|----------------------------------|-----------------|
| Global end of trial reached? | Yes |
| Global end of trial date | 19 January 2018 |
| Was the trial ended prematurely? | Yes |

Notes:

General information about the trial

Main objective of the trial:

The primary objective of this study was to assess the safety and tolerability of 3 vaccination schedules of Ad26 vector expressing the glycoprotein of the Ebola virus Mayinga variant (Ad26.ZEBOV) and Modified Vaccinia Ankara - Bavarian Nordic vector expressing the glycoproteins of Ebola virus, Sudan virus and Marburg virus and the nucleoprotein of Tai Forest virus (MVA-BN-Filo) administered intramuscularly (IM) as heterologous 2-dose regimens on Days 1 and 29, Days 1 and 57, or Days 1 and 85 (Groups 1 to 3).

Protection of trial subjects:

This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practices and applicable regulatory requirements. Safety evaluations included measurement of vital signs, clinical laboratory tests (Hematology, serum chemistry and urinalysis), assessment of adverse events (AEs) including reactogenicity, physical examinations, and electrocardiograms (ECG).

Background therapy: -

Evidence for comparator: -

| | |
|---|--------------|
| Actual start date of recruitment | 15 June 2015 |
| Long term follow-up planned | Yes |
| Long term follow-up rationale | Safety |
| Long term follow-up duration | 12 Months |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|---------------------|
| Country: Number of subjects enrolled | France: 197 |
| Country: Number of subjects enrolled | United Kingdom: 224 |
| Worldwide total number of subjects | 421 |
| EEA total number of subjects | 421 |

Notes:

Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 | 0 |

| | |
|---------------------------|-----|
| months) | |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 418 |
| From 65 to 84 years | 3 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

A total of 421 subjects were enrolled and treated. Of the 421 subjects, 406 subjects were enrolled in groups 1 to 3 (30 subjects in cohort I, 376 subjects in cohort II & III) and 15 subjects in group 4.

Period 1

| | |
|------------------------------|--------------------------|
| Period 1 title | REGIMEN (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator |

Arms

| | |
|------------------------------|---|
| Are arms mutually exclusive? | Yes |
| Arm title | Group1: Cohort I: Ad26.ZEBOV then MVA-BN-Filo,28-Day Interval |

Arm description:

Subjects received intramuscular (IM) injection of Ad26 vector expressing the glycoprotein of the Ebola virus Mayinga variant (Ad26.ZEBOV) at a dose of 5×10^{10} viral particles (vp) as Dose 1 on Day 1, followed by Modified Vaccinia Ankara - Bavarian Nordic vector expressing the glycoproteins of Ebola virus, Sudan virus and Marburg virus and the nucleoprotein of Tai Forest virus (MVA-BN-Filo) at a dose of 1×10^8 infectious units (Inf.U) (nominal titer) as Dose 2 on Day 29 in an open-label fashion.

| | |
|--|--------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Ad26.ZEBOV |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Suspension for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Subjects received IM injection of Ad26.ZEBOV at a dose of 5×10^{10} vp as Dose 1 on Day 1.

| | |
|--|--------------------------|
| Investigational medicinal product name | MVA-BN-Filo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Suspension for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Subjects received IM injection of MVA-BN-Filo at a dose of 1×10^8 Inf.U (nominal titer) as Dose 2 on Day 29.

| | |
|------------------|--|
| Arm title | Group 2:Cohort I: Ad26.ZEBOV then MVA-BN-Filo, 56-Day Interval |
|------------------|--|

Arm description:

Subjects received IM injection of Ad26.ZEBOV at a dose of 5×10^{10} vp as Dose 1 on Day 1, followed by MVA-BN-Filo at a dose of 1×10^8 Inf.U (nominal titer) as Dose 2 on Day 57 in an open-label fashion.

| | |
|--|--------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | MVA-BN-Filo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Suspension for injection |
| Routes of administration | Intramuscular use |

| | |
|--|--|
| Dosage and administration details: | |
| Subjects received IM injection of MVA-BN-Filo at a dose of 1×10^8 Inf.U (nominal titer) as Dose 2 on Day 57. | |
| Investigational medicinal product name | Ad26.ZEBOV |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Suspension for injection |
| Routes of administration | Intramuscular use |
| Dosage and administration details: | |
| Subjects received IM injection of Ad26.ZEBOV at a dose of 5×10^{10} vp as Dose 1 on Day 1. | |
| Arm title | Group 3:Cohort I: Ad26.ZEBOV then MVA-BN-Filo, 84-Day Interval |
| Arm description: | |
| Subjects received IM injection of Ad26.ZEBOV at a dose of 5×10^{10} vp as Dose 1 on Day 1, followed by MVA-BN-Filo at dose of 1×10^8 Inf.U (nominal titer) as Dose 2 on Day 85 in an open-label fashion. | |
| Arm type | Experimental |
| Investigational medicinal product name | MVA-BN-Filo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Suspension for injection |
| Routes of administration | Intramuscular use |
| Dosage and administration details: | |
| Subjects received IM injection of MVA-BN-Filo at a dose of 1×10^8 Inf.U (nominal titer) as Dose 2 on Day 85. | |
| Investigational medicinal product name | Ad26.ZEBOV |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Suspension for injection |
| Routes of administration | Intramuscular use |
| Dosage and administration details: | |
| Subjects received IM injection of Ad26.ZEBOV at a dose of 5×10^{10} vp as Dose 1 on Day 1. | |
| Arm title | Group1:Cohorts II & III:Ad26.ZEBOV/MVA-BN-Filo,28-Day Interval |
| Arm description: | |
| Subjects received IM injection of Ad26.ZEBOV at a dose of 5×10^{10} vp as Dose 1 on Day 1, followed by MVA-BN-Filo at a dose of 1×10^8 Inf.U (nominal titer) as Dose 2 on Day 29 in a blinded fashion. | |
| Arm type | Experimental |
| Investigational medicinal product name | MVA-BN-Filo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Suspension for injection |
| Routes of administration | Intramuscular use |
| Dosage and administration details: | |
| Subjects received IM injection of MVA-BN-Filo at a dose of 1×10^8 Inf.U (nominal titer) as Dose 2 on Day 29. | |
| Investigational medicinal product name | Ad26.ZEBOV |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Suspension for injection |
| Routes of administration | Intramuscular use |
| Dosage and administration details: | |
| Subjects received IM injection of Ad26.ZEBOV at a dose of 5×10^{10} vp as Dose 1 on Day 1. | |
| Arm title | Group 1: Cohorts II & III: Placebo, Placebo, 28-Day Interval |

Arm description:

Subjects received Placebo (0.9% saline) as Dose 1 on Day 1, followed by placebo (0.9% saline) as Dose 2 on Day 29 in a blinded fashion.

| | |
|--|------------------------|
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Subjects received Placebo (0.9% saline) as Dose 1 on Day 1, followed by placebo (0.9% saline) as Dose 2 on Day 29.

| | |
|------------------|--|
| Arm title | Group2:Cohorts II & III:Ad26.ZEBOV/MVA-BN-Filo,56-Day Interval |
|------------------|--|

Arm description:

Subjects received IM injection of Ad26.ZEBOV at a dose of 5×10^{10} vp as Dose 1 on Day 1, followed by MVA-BN-Filo at a dose of 1×10^8 Inf.U (nominal titer) as Dose 2 on Day 57 in a blinded fashion.

| | |
|--|--------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Ad26.ZEBOV |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Suspension for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Subjects received IM injection of Ad26.ZEBOV at a dose of 5×10^{10} vp as Dose 1 on Day 1.

| | |
|--|--------------------------|
| Investigational medicinal product name | MVA-BN-Filo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Suspension for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Subjects received IM injection of MVA-BN-Filo at a dose of 1×10^8 Inf.U (nominal titer) as Dose 2 on Day 57.

| | |
|------------------|--|
| Arm title | Group 2: Cohorts II & III: Placebo, Placebo, 56-Day Interval |
|------------------|--|

Arm description:

Subjects received Placebo (0.9% saline) as Dose 1 on Day 1, followed by placebo (0.9% saline) as Dose 2 on Day 57 in a blinded fashion.

| | |
|--|------------------------|
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Subjects received Placebo (0.9% saline) as Dose 1 on Day 1, followed by placebo (0.9% saline) as Dose 2 on Day 57.

| | |
|------------------|--|
| Arm title | Group3:Cohorts II & III:Ad26.ZEBOV/MVA-BN-Filo,84-Day Interval |
|------------------|--|

Arm description:

Subjects received IM injection of Ad26.ZEBOV at a dose of 5×10^{10} vp as Dose 1 on Day 1, followed by of MVA-BN-Filo at a dose of 1×10^8 Inf.U (nominal titer) as Dose 2 on Day 85 in a blinded fashion.

| | |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

| | |
|--|--------------------------|
| Investigational medicinal product name | MVA-BN-Filo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Suspension for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Subjects received IM injection of MVA-BN-Filo at a dose of 1×10^8 Inf.U (nominal titer) as Dose 2 on Day 85.

| | |
|--|--------------------------|
| Investigational medicinal product name | Ad26.ZEBOV |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Suspension for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Subjects received IM injection of Ad26.ZEBOV at a dose of 5×10^{10} vp as Dose 1 on Day 1.

| | |
|------------------|--|
| Arm title | Group 3: Cohorts II & III: Placebo, Placebo, 84-Day Interval |
|------------------|--|

Arm description:

Subjects received Placebo (0.9% saline) as Dose 1 on Day 1, followed by placebo (0.9% saline) as Dose 2 on Day 85 in a blinded fashion.

| | |
|--|------------------------|
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Subjects received Placebo (0.9% saline) as Dose 1 on Day 1, followed by placebo (0.9% saline) as Dose 2 on Day 85.

| | |
|------------------|---------------------|
| Arm title | Group 4: Ad26.ZEBOV |
|------------------|---------------------|

Arm description:

Subjects received IM injection of Ad26.ZEBOV at a dose of 5×10^{10} vp as Dose 1 on Day 1 in a blinded fashion.

| | |
|--|--------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Ad26.ZEBOV |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Suspension for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Subjects received IM injection of Ad26.ZEBOV at a dose of 5×10^{10} vp as Dose 1 on Day 1.

| | |
|------------------|------------------|
| Arm title | Group 4: Placebo |
|------------------|------------------|

Arm description:

Subjects received Placebo (0.9% saline) as Dose 1 on Day 1 in a blinded fashion.

| | |
|--|------------------------|
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Subjects received Placebo (0.9% saline) as Dose 1 on Day 1.

| Number of subjects in period 1 | Group1: Cohort I: Ad26.ZEBOV then MVA-BN-Filo,28-Day Interval | Group 2:Cohort I: Ad26.ZEBOV then MVA-BN-Filo, 56- Day Interval | Group 3:Cohort I: Ad26.ZEBOV then MVA-BN-Filo, 84- Day Interval |
|---------------------------------------|--|--|--|
| Started | 10 | 10 | 10 |
| Completed | 7 | 7 | 9 |
| Not completed | 3 | 3 | 1 |
| Consent withdrawn by subject | 2 | - | - |
| Physician decision | - | - | - |
| Adverse event, non-fatal | - | - | - |
| Other | - | - | 1 |
| Lost to follow-up | 1 | 3 | - |

| Number of subjects in period 1 | Group1:Cohorts II & III:Ad26.ZEBOV/MV A-BN-Filo,28-Day Interval | Group 1: Cohorts II & III: Placebo, Placebo, 28-Day Interval | Group2:Cohorts II & III:Ad26.ZEBOV/MV A-BN-Filo,56-Day Interval |
|---------------------------------------|--|---|--|
| Started | 112 | 13 | 114 |
| Completed | 97 | 12 | 98 |
| Not completed | 15 | 1 | 16 |
| Consent withdrawn by subject | 5 | 1 | 8 |
| Physician decision | - | - | 1 |
| Adverse event, non-fatal | 2 | - | 1 |
| Other | - | - | 1 |
| Lost to follow-up | 8 | - | 5 |

| Number of subjects in period 1 | Group 2: Cohorts II & III: Placebo, Placebo, 56-Day Interval | Group3:Cohorts II & III:Ad26.ZEBOV/MV A-BN-Filo,84-Day Interval | Group 3: Cohorts II & III: Placebo, Placebo, 84-Day Interval |
|---------------------------------------|---|--|---|
| Started | 13 | 106 | 18 |
| Completed | 11 | 94 | 13 |
| Not completed | 2 | 12 | 5 |
| Consent withdrawn by subject | - | 8 | 4 |
| Physician decision | 1 | 1 | - |
| Adverse event, non-fatal | - | - | - |
| Other | - | - | - |
| Lost to follow-up | 1 | 3 | 1 |

| Number of subjects in period 1 | Group 4: Ad26.ZEBOV | Group 4: Placebo |
|---------------------------------------|------------------------|------------------|
| Started | 13 | 2 |
| Completed | 13 | 2 |
| Not completed | 0 | 0 |
| Consent withdrawn by subject | - | - |

| | | |
|--------------------------|---|---|
| Physician decision | - | - |
| Adverse event, non-fatal | - | - |
| Other | - | - |
| Lost to follow-up | - | - |

Baseline characteristics

Reporting groups

| | |
|---|--|
| Reporting group title | Group1: Cohort I: Ad26.ZEBOV then MVA-BN-Filo,28-Day Interval |
| Reporting group description: Subjects received intramuscular (IM) injection of Ad26 vector expressing the glycoprotein of the Ebola virus Mayinga variant (Ad26.ZEBOV) at a dose of 5×10^{10} viral particles (vp) as Dose 1 on Day 1, followed by Modified Vaccinia Ankara - Bavarian Nordic vector expressing the glycoproteins of Ebola virus, Sudan virus and Marburg virus and the nucleoprotein of Tai Forest virus (MVA-BN-Filo) at a dose of 1×10^8 infectious units (Inf.U) (nominal titer) as Dose 2 on Day 29 in an open-label fashion. | |
| Reporting group title | Group 2:Cohort I: Ad26.ZEBOV then MVA-BN-Filo, 56-Day Interval |
| Reporting group description: Subjects received IM injection of Ad26.ZEBOV at a dose of 5×10^{10} vp as Dose 1 on Day 1, followed by MVA-BN-Filo at a dose of 1×10^8 Inf.U (nominal titer) as Dose 2 on Day 57 in an open-label fashion. | |
| Reporting group title | Group 3:Cohort I: Ad26.ZEBOV then MVA-BN-Filo, 84-Day Interval |
| Reporting group description: Subjects received IM injection of Ad26.ZEBOV at a dose of 5×10^{10} vp as Dose 1 on Day 1, followed by MVA-BN-Filo at dose of 1×10^8 Inf.U (nominal titer) as Dose 2 on Day 85 in an open-label fashion. | |
| Reporting group title | Group1:Cohorts II & III:Ad26.ZEBOV/MVA-BN-Filo,28-Day Interval |
| Reporting group description: Subjects received IM injection of Ad26.ZEBOV at a dose of 5×10^{10} vp as Dose 1 on Day 1, followed by MVA-BN-Filo at a dose of 1×10^8 Inf.U (nominal titer) as Dose 2 on Day 29 in a blinded fashion. | |
| Reporting group title | Group 1: Cohorts II & III: Placebo, Placebo, 28-Day Interval |
| Reporting group description: Subjects received Placebo (0.9% saline) as Dose 1 on Day 1, followed by placebo (0.9% saline) as Dose 2 on Day 29 in a blinded fashion. | |
| Reporting group title | Group2:Cohorts II & III:Ad26.ZEBOV/MVA-BN-Filo,56-Day Interval |
| Reporting group description: Subjects received IM injection of Ad26.ZEBOV at a dose of 5×10^{10} vp as Dose 1 on Day 1, followed by MVA-BN-Filo at a dose of 1×10^8 Inf.U (nominal titer) as Dose 2 on Day 57 in a blinded fashion. | |
| Reporting group title | Group 2: Cohorts II & III: Placebo, Placebo, 56-Day Interval |
| Reporting group description: Subjects received Placebo (0.9% saline) as Dose 1 on Day 1, followed by placebo (0.9% saline) as Dose 2 on Day 57 in a blinded fashion. | |
| Reporting group title | Group3:Cohorts II & III:Ad26.ZEBOV/MVA-BN-Filo,84-Day Interval |
| Reporting group description: Subjects received IM injection of Ad26.ZEBOV at a dose of 5×10^{10} vp as Dose 1 on Day 1, followed by of MVA-BN-Filo at a dose of 1×10^8 Inf.U (nominal titer) as Dose 2 on Day 85 in a blinded fashion. | |
| Reporting group title | Group 3: Cohorts II & III: Placebo, Placebo, 84-Day Interval |
| Reporting group description: Subjects received Placebo (0.9% saline) as Dose 1 on Day 1, followed by placebo (0.9% saline) as Dose 2 on Day 85 in a blinded fashion. | |
| Reporting group title | Group 4: Ad26.ZEBOV |
| Reporting group description: Subjects received IM injection of Ad26.ZEBOV at a dose of 5×10^{10} vp as Dose 1 on Day 1 in a blinded fashion. | |
| Reporting group title | Group 4: Placebo |
| Reporting group description: Subjects received Placebo (0.9% saline) as Dose 1 on Day 1 in a blinded fashion. | |

| Reporting group values | Group1: Cohort I: Ad26.ZEBOV then MVA-BN-Filo,28-Day Interval | Group 2:Cohort I: Ad26.ZEBOV then MVA-BN-Filo, 56- Day Interval | Group 3:Cohort I: Ad26.ZEBOV then MVA-BN-Filo, 84- Day Interval |
|---|--|--|--|
| Number of subjects | 10 | 10 | 10 |
| Title for AgeCategorical Units: subjects | | | |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 10 | 10 | 10 |
| From 65 to 84 years | 0 | 0 | 0 |
| 85 years and over | 0 | 0 | 0 |
| Title for AgeContinuous Units: years | | | |
| arithmetic mean | 34.2 | 47.4 | 38.7 |
| standard deviation | ± 12.95 | ± 16.53 | ± 13.99 |
| Title for Gender Units: subjects | | | |
| Female | 4 | 6 | 7 |
| Male | 6 | 4 | 3 |

| Reporting group values | Group1:Cohorts II & III:Ad26.ZEBOV/MV A-BN-Filo,28-Day Interval | Group 1: Cohorts II & III: Placebo, Placebo, 28-Day Interval | Group2:Cohorts II & III:Ad26.ZEBOV/MV A-BN-Filo,56-Day Interval |
|---|--|---|--|
| Number of subjects | 112 | 13 | 114 |
| Title for AgeCategorical Units: subjects | | | |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 111 | 13 | 114 |
| From 65 to 84 years | 1 | 0 | 0 |
| 85 years and over | 0 | 0 | 0 |
| Title for AgeContinuous Units: years | | | |
| arithmetic mean | 41 | 39.1 | 41 |
| standard deviation | ± 15 | ± 13.9 | ± 14.02 |
| Title for Gender Units: subjects | | | |
| Female | 57 | 6 | 62 |
| Male | 55 | 7 | 52 |

| Reporting group values | Group 2: Cohorts II & III: Placebo, Placebo, 56-Day Interval | Group3:Cohorts II & III:Ad26.ZEBOV/MV A-BN-Filo,84-Day Interval | Group 3: Cohorts II & III: Placebo, Placebo, 84-Day Interval |
|---|---|--|---|
| Number of subjects | 13 | 106 | 18 |
| Title for AgeCategorical Units: subjects | | | |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 13 | 104 | 18 |

| | | | |
|---------------------|---|---|---|
| From 65 to 84 years | 0 | 2 | 0 |
| 85 years and over | 0 | 0 | 0 |

| | | | |
|--|-----------------|-----------------|-----------------|
| Title for AgeContinuous Units: years arithmetic mean standard deviation | 38.2 ± 13.66 | 38.3 ± 14.34 | 41.1 ± 15.11 |
| Title for Gender Units: subjects | | | |
| Female | 8 | 53 | 10 |
| Male | 5 | 53 | 8 |

| Reporting group values | Group 4: Ad26.ZEBOV | Group 4: Placebo | Total |
|--|------------------------|------------------|-------|
| Number of subjects | 13 | 2 | 421 |
| Title for AgeCategorical Units: subjects | | | |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 13 | 2 | 418 |
| From 65 to 84 years | 0 | 0 | 3 |
| 85 years and over | 0 | 0 | 0 |
| Title for AgeContinuous Units: years arithmetic mean standard deviation | 37.9 ± 11.37 | 47 ± 4.24 | - |
| Title for Gender Units: subjects | | | |
| Female | 3 | 1 | 217 |
| Male | 10 | 1 | 204 |

End points

End points reporting groups

| | |
|---|--|
| Reporting group title | Group1: Cohort I: Ad26.ZEBOV then MVA-BN-Filo,28-Day Interval |
| Reporting group description: Subjects received intramuscular (IM) injection of Ad26 vector expressing the glycoprotein of the Ebola virus Mayinga variant (Ad26.ZEBOV) at a dose of 5×10^{10} viral particles (vp) as Dose 1 on Day 1, followed by Modified Vaccinia Ankara - Bavarian Nordic vector expressing the glycoproteins of Ebola virus, Sudan virus and Marburg virus and the nucleoprotein of Tai Forest virus (MVA-BN-Filo) at a dose of 1×10^8 infectious units (Inf.U) (nominal titer) as Dose 2 on Day 29 in an open-label fashion. | |
| Reporting group title | Group 2:Cohort I: Ad26.ZEBOV then MVA-BN-Filo, 56-Day Interval |
| Reporting group description: Subjects received IM injection of Ad26.ZEBOV at a dose of 5×10^{10} vp as Dose 1 on Day 1, followed by MVA-BN-Filo at a dose of 1×10^8 Inf.U (nominal titer) as Dose 2 on Day 57 in an open-label fashion. | |
| Reporting group title | Group 3:Cohort I: Ad26.ZEBOV then MVA-BN-Filo, 84-Day Interval |
| Reporting group description: Subjects received IM injection of Ad26.ZEBOV at a dose of 5×10^{10} vp as Dose 1 on Day 1, followed by MVA-BN-Filo at dose of 1×10^8 Inf.U (nominal titer) as Dose 2 on Day 85 in an open-label fashion. | |
| Reporting group title | Group1:Cohorts II & III:Ad26.ZEBOV/MVA-BN-Filo,28-Day Interval |
| Reporting group description: Subjects received IM injection of Ad26.ZEBOV at a dose of 5×10^{10} vp as Dose 1 on Day 1, followed by MVA-BN-Filo at a dose of 1×10^8 Inf.U (nominal titer) as Dose 2 on Day 29 in a blinded fashion. | |
| Reporting group title | Group 1: Cohorts II & III: Placebo, Placebo, 28-Day Interval |
| Reporting group description: Subjects received Placebo (0.9% saline) as Dose 1 on Day 1, followed by placebo (0.9% saline) as Dose 2 on Day 29 in a blinded fashion. | |
| Reporting group title | Group2:Cohorts II & III:Ad26.ZEBOV/MVA-BN-Filo,56-Day Interval |
| Reporting group description: Subjects received IM injection of Ad26.ZEBOV at a dose of 5×10^{10} vp as Dose 1 on Day 1, followed by MVA-BN-Filo at a dose of 1×10^8 Inf.U (nominal titer) as Dose 2 on Day 57 in a blinded fashion. | |
| Reporting group title | Group 2: Cohorts II & III: Placebo, Placebo, 56-Day Interval |
| Reporting group description: Subjects received Placebo (0.9% saline) as Dose 1 on Day 1, followed by placebo (0.9% saline) as Dose 2 on Day 57 in a blinded fashion. | |
| Reporting group title | Group3:Cohorts II & III:Ad26.ZEBOV/MVA-BN-Filo,84-Day Interval |
| Reporting group description: Subjects received IM injection of Ad26.ZEBOV at a dose of 5×10^{10} vp as Dose 1 on Day 1, followed by MVA-BN-Filo at a dose of 1×10^8 Inf.U (nominal titer) as Dose 2 on Day 85 in a blinded fashion. | |
| Reporting group title | Group 3: Cohorts II & III: Placebo, Placebo, 84-Day Interval |
| Reporting group description: Subjects received Placebo (0.9% saline) as Dose 1 on Day 1, followed by placebo (0.9% saline) as Dose 2 on Day 85 in a blinded fashion. | |
| Reporting group title | Group 4: Ad26.ZEBOV |
| Reporting group description: Subjects received IM injection of Ad26.ZEBOV at a dose of 5×10^{10} vp as Dose 1 on Day 1 in a blinded fashion. | |
| Reporting group title | Group 4: Placebo |
| Reporting group description: Subjects received Placebo (0.9% saline) as Dose 1 on Day 1 in a blinded fashion. | |

Primary: Group 1, 2 and 3: Percentage of Subjects with Adverse Events (Unsolicited Adverse Events)

| | |
|-----------------|---|
| End point title | Group 1, 2 and 3: Percentage of Subjects with Adverse Events (Unsolicited Adverse Events) ^{[1][2]} |
|-----------------|---|

End point description:

An adverse event (AE) is any untoward medical occurrence in a clinical study subject administered a medicinal product, it does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal product. Full Analysis set included all subjects who were randomized and received at least one dose of study vaccine, regardless of the occurrence of protocol deviations.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

From signing of ICF (Inform Consent Form) Up to 42-day post-dose 2 visit (Day 71 for Group 1; Day 99 for Group 2; and Day 127 for Group 3)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics were done, no inferential statistical analyses were performed.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint was planned to be reported for the specified arms only.

| End point values | Group1: Cohort I: Ad26.ZEBOV then MVA-BN-Filo, 28-Day Interval | Group 2: Cohort I: Ad26.ZEBOV then MVA-BN-Filo, 56-Day Interval | Group 3: Cohort I: Ad26.ZEBOV then MVA-BN-Filo, 84-Day Interval | Group1: Cohort s II & III: Ad26.ZEBOV/MVA-BN-Filo, 28-Day Interval |
|-------------------------------|--|---|---|--|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 10 | 10 | 10 | 112 |
| Units: Percentage of subjects | | | | |
| number (not applicable) | 40.0 | 60.0 | 60.0 | 55.4 |

| End point values | Group 1: Cohorts II & III: Placebo, Placebo, 28-Day Interval | Group2: Cohort s II & III: Ad26.ZEBOV/MVA-BN-Filo, 56-Day Interval | Group 2: Cohorts II & III: Placebo, Placebo, 56-Day Interval | Group3: Cohort s II & III: Ad26.ZEBOV/MVA-BN-Filo, 84-Day Interval |
|-------------------------------|--|--|--|--|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 13 | 114 | 13 | 106 |
| Units: Percentage of subjects | | | | |
| number (not applicable) | 46.2 | 45.6 | 53.8 | 43.4 |

| End point values | Group 3: Cohorts II & III: Placebo, Placebo, 84-Day Interval | | | |
|------------------|--|--|--|--|
|------------------|--|--|--|--|

| | | | | |
|-------------------------------|-----------------|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 18 | | | |
| Units: Percentage of subjects | | | | |
| number (not applicable) | 44.4 | | | |

Statistical analyses

No statistical analyses for this end point

Primary: Group 1, 2 and 3: Percentage of Subjects with Serious Adverse Events (SAEs)

| | |
|-----------------|---|
| End point title | Group 1, 2 and 3: Percentage of Subjects with Serious Adverse Events (SAEs) ^{[3][4]} |
|-----------------|---|

End point description:

SAEs are any untoward medical occurrence that at any dose results in death, is life-threatening (the subject was at risk of death at the time of the event. It does not refer to an event that hypothetically might have caused death if it were more severe), requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product. Full Analysis set included all subjects who were randomized and received at least one dose of study vaccine, regardless of the occurrence of protocol deviations.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

From signing of ICF up to end of the study (Day 365)

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics were done, no inferential statistical analyses were performed.

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint was planned to be reported for the specified arms only.

| End point values | Group1: Cohort I: Ad26.ZEBOV then MVA-BN-Filo,28-Day Interval | Group 2:Cohort I: Ad26.ZEBOV then MVA-BN-Filo, 56-Day Interval | Group 3:Cohort I: Ad26.ZEBOV then MVA-BN-Filo, 84-Day Interval | Group1:Cohort s II & III:Ad26.ZEBOV/MVA-BN-Filo,28-Day Interval |
|-------------------------------|---|--|--|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 10 | 10 | 10 | 112 |
| Units: Percentage of subjects | | | | |
| number (not applicable) | 0 | 10.0 | 0 | 1.8 |

| End point values | Group 1: Cohorts II & III: Placebo, Placebo, 28-Day Interval | Group2:Cohort s II & III:Ad26.ZEBOV/MVA-BN-Filo,56-Day Interval | Group 2: Cohorts II & III: Placebo, Placebo, 56-Day Interval | Group3:Cohort s II & III:Ad26.ZEBOV/MVA-BN-Filo,84-Day Interval |
|-------------------------------|--|---|--|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 13 | 114 | 13 | 106 |
| Units: Percentage of subjects | | | | |

| | | | | |
|-------------------------|---|-----|-----|-----|
| number (not applicable) | 0 | 3.5 | 7.7 | 4.7 |
|-------------------------|---|-----|-----|-----|

| | | | | |
|-------------------------------|---|--|--|--|
| End point values | Group 3: Cohorts II & III: Placebo, Placebo, 84- Day Interval | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 18 | | | |
| Units: Percentage of subjects | | | | |
| number (not applicable) | 5.6 | | | |

Statistical analyses

No statistical analyses for this end point

Primary: Group 1, 2 and 3: Percentage of Subjects with Immediate Reportable Events (IREs)

| | |
|-----------------|--|
| End point title | Group 1, 2 and 3: Percentage of Subjects with Immediate Reportable Events (IREs) ^[5] ^[6] |
|-----------------|--|

End point description:

Any event of neuroimmunologic significance categorized as IREs which includes Cranial nerve disorders, including Paralysis/paresis, Optic neuritis, Multiple sclerosis, Transverse myelitis, Guillain-Barre syndrome, Miller Fisher syndrome, Bickerstaff's encephalitis, Acute disseminated encephalomyelitis (including site specific variants: non-infectious encephalitis, encephalomyelitis, myelitis, myeloradiculomyelitis), Myasthenia gravis, Lambert-Eaton myasthenic syndrome, Immune-mediated peripheral neuropathies, plexopathies (including chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy and polyneuropathies associated with monoclonal gammopathy), Narcolepsy, Isolated paresthesia of greater than (>) 7 days duration. Full Analysis set included all subjects who were randomized, received at least one dose of study vaccine, regardless of the occurrence of protocol deviations. Here, '99999' defines that no immediate reportable events indicated for cohort 1.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

From signing of ICF Up to end of the study (Day 365)

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics were done, no inferential statistical analyses were performed.

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint was planned to be reported for the specified arms only.

| | | | | |
|-------------------------------|---|--|--|--|
| End point values | Group1: Cohort I: Ad26.ZEBOV then MVA-BN-Filo,28-Day Interval | Group 2:Cohort I: Ad26.ZEBOV then MVA-BN-Filo, 56-Day Interval | Group 3:Cohort I: Ad26.ZEBOV then MVA-BN-Filo, 84-Day Interval | Group1:Cohorts II & III:Ad26.ZEBOV/MVA-BN-Filo,28-Day Interval |
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 10 | 10 | 10 | 112 |
| Units: Percentage of subjects | | | | |
| number (not applicable) | 99999 | 99999 | 99999 | 0 |

| End point values | Group 1: Cohorts II & III: Placebo, Placebo, 28-Day Interval | Group2:Cohorts II & III:Ad26.ZEBO V/MVA-BN-Filo,56-Day Interval | Group 2: Cohorts II & III: Placebo, Placebo, 56-Day Interval | Group3:Cohorts II & III:Ad26.ZEBO V/MVA-BN-Filo,84-Day Interval |
|-------------------------------|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 13 | 114 | 13 | 106 |
| Units: Percentage of subjects | | | | |
| number (not applicable) | 0 | 1.8 | 0 | 1.9 |

| End point values | Group 3: Cohorts II & III: Placebo, Placebo, 84-Day Interval | | | |
|-------------------------------|---|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 18 | | | |
| Units: Percentage of subjects | | | | |
| number (not applicable) | 0 | | | |

Statistical analyses

No statistical analyses for this end point

Primary: Group 1, 2 and 3: Percentage of Subjects with Solicited Local Adverse Events

| | |
|-----------------|--|
| End point title | Group 1, 2 and 3: Percentage of Subjects with Solicited Local Adverse Events ^{[7][8]} |
|-----------------|--|

End point description:

Subjects with solicited local (injection site) adverse events were instructed on how to note occurrences of erythema, induration/swelling (measured using the ruler supplied), pain/tenderness and itching at the injection site in the evening after each study vaccine administration and then daily for the next 7 days in the diary. Full Analysis set included all subjects who were randomized and received at least one dose of study vaccine, regardless of the occurrence of protocol deviations. Here 'n' indicates the number of subjects who were analyzed at specified timepoint for each arm.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Up to 7 days Post Dose 1 (Day 8 for Group 1, 2 and 3) and Post Dose 2 (Day 35, 63 and 91 for Group 1, 2 and 3 respectively)

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics were done, no inferential statistical analyses were performed.

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint was planned to be reported for the specified arms only.

| End point values | Group1: Cohort I: Ad26.ZEBOV then MVA-BN-Filo,28-Day Interval | Group 2:Cohort I: Ad26.ZEBOV then MVA-BN-Filo, 56-Day Interval | Group 3:Cohort I: Ad26.ZEBOV then MVA-BN-Filo, 84-Day Interval | Group1:Cohort s II & III:Ad26.ZEBOV/MVA-BN-Filo,28-Day Interval |
|--|---|--|--|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 10 | 10 | 10 | 112 |
| Units: Percentage of subjects | | | | |
| number (not applicable) | | | | |
| Post-dose 1 (n=10,10,10,112,13, 114,13,106,18) | 80.0 | 60.0 | 80.0 | 56.3 |
| Post-dose 2(n=8,9,9, 91,10,83,7,62,11) | 50.0 | 55.6 | 88.9 | 50.5 |

| End point values | Group 1: Cohorts II & III: Placebo, Placebo, 28-Day Interval | Group2:Cohort s II & III:Ad26.ZEBOV/MVA-BN-Filo,56-Day Interval | Group 2: Cohorts II & III: Placebo, Placebo, 56-Day Interval | Group3:Cohort s II & III:Ad26.ZEBOV/MVA-BN-Filo,84-Day Interval |
|--|--|---|--|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 13 | 114 | 13 | 106 |
| Units: Percentage of subjects | | | | |
| number (not applicable) | | | | |
| Post-dose 1 (n=10,10,10,112,13, 114,13,106,18) | 23.1 | 57.0 | 15.4 | 73.6 |
| Post-dose 2(n=8,9,9, 91,10,83,7,62,11) | 20.0 | 59.0 | 0 | 66.1 |

| End point values | Group 3: Cohorts II & III: Placebo, Placebo, 84-Day Interval | | | |
|--|--|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 18 | | | |
| Units: Percentage of subjects | | | | |
| number (not applicable) | | | | |
| Post-dose 1 (n=10,10,10,112,13, 114,13,106,18) | 22.2 | | | |
| Post-dose 2(n=8,9,9, 91,10,83,7,62,11) | 0 | | | |

Statistical analyses

No statistical analyses for this end point

Primary: Group 1, 2 and 3: Percentage of Subjects with Solicited Systemic Adverse Events

| | |
|-----------------|--|
| End point title | Group 1, 2 and 3: Percentage of Subjects with Solicited Systemic Adverse Events ^[9] ^[10] |
|-----------------|--|

End point description:

An AE is defined as any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal product. Solicited systemic AEs included fever (defined as body temperature of 38 degree Celsius or higher), Headache, fatigue/Malaise, myalgia, nausea/vomiting, arthralgia, chills. Full Analysis set included all subjects who were randomized and received at least one dose of study vaccine, regardless of the occurrence of protocol deviations. Here 'n' signifies number of subjects who were analyzed at specified timepoint for each arm.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Up to 7 days Post Dose 1 (Day 8 for Group 1, 2 and 3) and Post Dose 2 (Day 35, 63 and 91 for Group 1, 2 and 3 respectively)

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics were done, no inferential statistical analyses were performed.

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint was planned to be reported for the specified arms only.

| End point values | Group1: Cohort I: Ad26.ZEBOV then MVA-BN-Filo,28-Day Interval | Group 2:Cohort I: Ad26.ZEBOV then MVA-BN-Filo, 56-Day Interval | Group 3:Cohort I: Ad26.ZEBOV then MVA-BN-Filo, 84-Day Interval | Group1:Cohort s II & III:Ad26.ZEBO V/MVA-BN-Filo,28-Day Interval |
|--|---|--|--|--|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 10 | 10 | 10 | 112 |
| Units: Percentage of subjects | | | | |
| number (not applicable) | | | | |
| Post-dose 1 (n=10,10,10,112,13,114,13,106,18) | 80.0 | 100.0 | 100.0 | 79.5 |
| Post-dose 2 (n=8,9,9,91,10,83,7,62,11) | 75.0 | 55.6 | 55.6 | 46.2 |

| End point values | Group 1: Cohorts II & III: Placebo, Placebo, 28-Day Interval | Group2:Cohort s II & III:Ad26.ZEBO V/MVA-BN-Filo,56-Day Interval | Group 2: Cohorts II & III: Placebo, Placebo, 56-Day Interval | Group3:Cohort s II & III:Ad26.ZEBO V/MVA-BN-Filo,84-Day Interval |
|--|--|--|--|--|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 13 | 114 | 13 | 106 |
| Units: Percentage of subjects | | | | |
| number (not applicable) | | | | |
| Post-dose 1 (n=10,10,10,112,13,114,13,106,18) | 53.8 | 73.7 | 61.5 | 77.4 |
| Post-dose 2 (n=8,9,9,91,10,83,7,62,11) | 50.0 | 43.4 | 28.6 | 61.3 |

| End point values | Group 3: Cohorts II & III: Placebo, Placebo, 84-Day Interval | | | |
|------------------|--|--|--|--|
|------------------|--|--|--|--|

| | | | | |
|--|-----------------|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 18 | | | |
| Units: Percentage of subjects | | | | |
| number (not applicable) | | | | |
| Post-dose 1 (n=10,10,10,112,13,114,13,106,18) | 38.9 | | | |
| Post-dose 2 (n=8,9,9,91,10,83,7,62,11) | 36.4 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Group 4: Percentage of Subjects with Adverse Events (Unsolicited Adverse Events)

| | |
|-----------------|--|
| End point title | Group 4: Percentage of Subjects with Adverse Events (Unsolicited Adverse Events) ^[11] |
|-----------------|--|

End point description:

An AE is any untoward medical occurrence in a clinical study subject administered a medicinal product, it does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal product. Full Analysis set included all subjects who were randomized and received at least one dose of study vaccine, regardless of the occurrence of protocol deviations.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to 28-day post vaccination visit (Day 29 for Group 4)

Notes:

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint was planned to be reported for the specified arms only.

| End point values | Group 4: Ad26.ZEBOV | Group 4: Placebo | | |
|-------------------------------|------------------------|---------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 13 | 2 | | |
| Units: Percentage of subjects | | | | |
| number (not applicable) | 46.2 | 50.0 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Group 4: Percentage of Subjects with Serious Adverse Events

| | |
|-----------------|--|
| End point title | Group 4: Percentage of Subjects with Serious Adverse |
|-----------------|--|

End point description:

SAEs are any untoward medical occurrence that at any dose results in death, is life-threatening (the subject was at risk of death at the time of the event. It does not refer to an event that hypothetically might have caused death if it were more severe), requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital

anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product. Full Analysis set includes all subjects who were randomized and received at least one dose of study vaccine, regardless of the occurrence of protocol deviations.

| | |
|--|-----------|
| End point type | Secondary |
| End point timeframe: | |
| From signing of ICF up to end of the study (Day 365) | |

Notes:

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint was planned to be reported for the specified arms only.

| End point values | Group 4: Ad26.ZEBOV | Group 4: Placebo | | |
|-------------------------------|------------------------|---------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 13 | 2 | | |
| Units: Percentage of subjects | | | | |
| number (not applicable) | 15.4 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Group 4: Percentage of Subjects with Immediate Reportable Events (IREs)

| | |
|-----------------|---|
| End point title | Group 4: Percentage of Subjects with Immediate Reportable Events (IREs) ^[13] |
|-----------------|---|

End point description:

Any event of neuroimmunologic significance categorized as IREs which includes Cranial nerve disorders, including Paralysis/paresis, Optic neuritis, Multiple sclerosis, Transverse myelitis, Guillain-Barre syndrome, including Miller Fisher syndrome, Bickerstaff's encephalitis, Acute disseminated encephalomyelitis (including site specific variants: non-infectious encephalitis, encephalomyelitis, myelitis, myeloradiculomyelitis), Myasthenia gravis and Lambert-Eaton myasthenic syndrome, Immune-mediated peripheral neuropathies and plexopathies (including chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy and polyneuropathies associated with monoclonal gammopathy), Narcolepsy, Isolated paresthesia of >7 days duration. Full Analysis set included all subjects who were randomized and received at least one dose of study vaccine, regardless of the occurrence of protocol deviations. Here, '99999' defines that no immediate reportable events indicated for Group 4.

| | |
|--|-----------|
| End point type | Secondary |
| End point timeframe: | |
| From signing of ICF up to end of the study (Day 365) | |

Notes:

[13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint was planned to be reported for the specified arms only.

| End point values | Group 4: Ad26.ZEBOV | Group 4: Placebo | | |
|-------------------------------|------------------------|---------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 13 | 2 | | |
| Units: Percentage of subjects | | | | |
| number (not applicable) | 99999 | 99999 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Group 4: Percentage of Subjects with Solicited Local Adverse Events

| | |
|-----------------|---|
| End point title | Group 4: Percentage of Subjects with Solicited Local Adverse Events ^[14] |
|-----------------|---|

End point description:

Solicited adverse events are precisely defined events that subjects are specifically asked about and which are noted by subjects in the diary. Subjects with Solicited Local (Injection Site) Adverse Events were instructed on how to note occurrences of erythema, induration/swelling (measured using the ruler supplied), pain/tenderness and itching at the injection site in the evening after each study vaccine administration and then daily for the next 7 days in the diary. Full Analysis set included all subjects who were randomized and received at least one dose of study vaccine, regardless of the occurrence of protocol deviations.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to 7 days Post-dose 1 (Day 8)

Notes:

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint was planned to be reported for the specified arms only.

| End point values | Group 4: Ad26.ZEBOV | Group 4: Placebo | | |
|-------------------------------|------------------------|---------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 13 | 2 | | |
| Units: Percentage of subjects | | | | |
| number (not applicable) | 61.5 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Group 4: Percentage of Subjects with Solicited Systemic Adverse Events

| | |
|-----------------|--|
| End point title | Group 4: Percentage of Subjects with Solicited Systemic Adverse Events ^[15] |
|-----------------|--|

End point description:

An AE is defined as any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal product. Solicited systemic AEs included fever (defined as body temperature of 38°C or higher), Headache, fatigue/Malaise, myalgia, nausea/vomiting, arthralgia, chills. Full Analysis set included all subjects who were randomized and received at least one dose of study vaccine, regardless of the occurrence of protocol deviations.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to 7 days Post-dose 1 (Day 8)

Notes:

[15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint was planned to be reported for the specified arms only.

| End point values | Group 4: Ad26.ZEBOV | Group 4: Placebo | | |
|-------------------------------|------------------------|---------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 13 | 2 | | |
| Units: Percentage of subjects | | | | |
| number (not applicable) | 84.6 | 50.0 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects with Anti-Ebola Virus (EBOV) Glycoprotein (GP) Binding Antibody Responses

| | |
|-----------------|--|
| End point title | Percentage of Subjects with Anti-Ebola Virus (EBOV) Glycoprotein (GP) Binding Antibody Responses ^[16] |
|-----------------|--|

End point description:

Humoral immune responses were measured by binding antibody responses using EBOV GP Filovirus Animal Nonclinical Group (FANG) enzyme-linked immunosorbent assay (ELISA). The per Protocol analysis set included all randomized and vaccinated subjects, who received both the dose 1 and dose 2 (administered not more than 10 days outside the visit window) vaccinations, had immunogenicity data from baseline and at least one post-vaccination evaluable immunogenicity sample, and had no major protocol violations influencing the immune response. Here, 99999 indicates that data was not reported as no subjects analyzed in the respective group at specified timepoint. Here 'N' (number of subjects analyzed) signifies number of subjects evaluable for this endpoint and 'n' indicates the number of subjects who were analyzed at specified timepoint for each arm.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At 21 days post Dose 2 (Day 50 for Group 1; Day 78 for Group 2; and Day 106 for Group 3)

Notes:

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint was planned to be reported for the specified arms only.

| End point values | Group1:Cohorts II & III:Ad26.ZEBOV/MVA-BN-Filo,28-Day Interval | Group 1: Cohorts II & III: Placebo, 28-Day Interval | Group2:Cohorts II & III:Ad26.ZEBOV/MVA-BN-Filo,56-Day Interval | Group 2: Cohorts II & III: Placebo, 56-Day Interval |
|-------------------------------|--|---|--|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 80 | 8 | 70 | 7 |
| Units: Percentage of subjects | | | | |
| number (not applicable) | | | | |
| Day 50 (n=77, 7, 0, 0, 0, 0) | 98.7 | 0 | 99999 | 99999 |
| Day 78 (n=0, 0, 69, 7, 0, 0) | 99999 | 99999 | 100 | 0 |
| Day 106 (n=0, 0, 0, 0, 48, 6) | 99999 | 99999 | 99999 | 99999 |

| End point values | Group3:Cohorts II & III:Ad26.ZEBOV/MVA-BN-Filo,84-Day Interval | Group 3: Cohorts II & III: Placebo, Placebo, 84-Day Interval | | |
|-------------------------------|--|--|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 51 | 6 | | |
| Units: Percentage of subjects | | | | |
| number (not applicable) | | | | |
| Day 50 (n=77, 7, 0, 0, 0, 0) | 99999 | 99999 | | |
| Day 78 (n=0, 0, 69, 7, 0, 0) | 99999 | 99999 | | |
| Day 106 (n=0, 0, 0, 0, 48, 6) | 100 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Screening up to Day 365

| | |
|-----------------|----------------|
| Assessment type | Non-systematic |
|-----------------|----------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 19.1 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|---|
| Reporting group title | Group1:Cohort I:Ad26.ZEBOV then MVA-BN-Filo,28-Day Interval |
|-----------------------|---|

Reporting group description:

Subjects received intramuscular (IM) injection of Ad26 vector expressing the glycoprotein of the Ebola virus Mayinga variant (Ad26.ZEBOV) at a dose of 5×10^{10} viral particles (vp) as Dose 1 on Day 1, followed by Modified Vaccinia Ankara – Bavarian Nordic vector expressing the glycoproteins of Ebola virus, Sudan virus and Marburg virus and the nucleoprotein of Tai Forest virus (MVA-BN-Filo) at a dose of 1×10^8 infectious units (Inf.U) (nominal titer) as Dose 2 on Day 29 in an open-label fashion.

| | |
|-----------------------|--|
| Reporting group title | Group 2:Cohort I: Ad26.ZEBOV then MVA-BN-Filo, 56-Day Interval |
|-----------------------|--|

Reporting group description:

Subjects received IM injection of Ad26.ZEBOV at a dose of 5×10^{10} vp as Dose 1 on Day 1, followed by MVA-BN-Filo at a dose of 1×10^8 Inf.U (nominal titer) as Dose 2 on Day 57 in an open-label fashion.

| | |
|-----------------------|--|
| Reporting group title | Group 3:Cohort I: Ad26.ZEBOV then MVA-BN-Filo, 84-Day Interval |
|-----------------------|--|

Reporting group description:

Subjects received IM injection of Ad26.ZEBOV at a dose of 5×10^{10} vp as Dose 1 on Day 1, followed by MVA-BN-Filo at a dose of 1×10^8 Inf.U (nominal titer) as Dose 2 on Day 85 in an open-label fashion.

| | |
|-----------------------|--|
| Reporting group title | Group1:Cohorts II & III:Ad26.ZEBOV/MVA-BN-Filo,28-Day Interval |
|-----------------------|--|

Reporting group description:

Subjects received IM injection of Ad26.ZEBOV at a dose of 5×10^{10} vp as Dose 1 on Day 1, followed by MVA-BN-Filo at a dose of 1×10^8 Inf.U (nominal titer) as Dose 2 on Day 29 in a blinded fashion.

| | |
|-----------------------|--|
| Reporting group title | Group 1: Cohorts II & III: Placebo, Placebo, 28-Day Interval |
|-----------------------|--|

Reporting group description:

Subjects received Placebo (0.9% saline) as Dose 1 on Day 1, followed by placebo (0.9% saline) as Dose 2 on Day 29 in a blinded fashion.

| | |
|-----------------------|--|
| Reporting group title | Group2:Cohorts II & III:Ad26.ZEBOV/MVA-BN-Filo,56-Day Interval |
|-----------------------|--|

Reporting group description:

Subjects received IM injection of Ad26.ZEBOV at a dose of 5×10^{10} vp as Dose 1 on Day 1, followed by MVA-BN-Filo at a dose of 1×10^8 Inf.U (nominal titer) as Dose 2 on Day 57 in a blinded fashion.

| | |
|-----------------------|--|
| Reporting group title | Group 2: Cohorts II & III: Placebo, Placebo, 56-Day Interval |
|-----------------------|--|

Reporting group description:

Subjects received Placebo (0.9% saline) as Dose 1 on Day 1, followed by placebo (0.9% saline) as Dose 2 on Day 56 in a blinded fashion.

| | |
|-----------------------|--|
| Reporting group title | Group3:Cohorts II & III:Ad26.ZEBOV/MVA-BN-Filo,84-Day Interval |
|-----------------------|--|

Reporting group description:

Subjects received IM injection of Ad26.ZEBOV at a dose of 5×10^{10} vp as Dose 1 on Day 1, followed by MVA-BN-Filo at a dose of 1×10^8 Inf.U (nominal titer) as Dose 2 on Day 85 in a blinded fashion.

| | |
|-----------------------|--|
| Reporting group title | Group 3: Cohorts II & III: Placebo, Placebo, 84-Day Interval |
|-----------------------|--|

Reporting group description:

Subjects received Placebo (0.9% saline) as Dose 1 on Day 1, followed by placebo (0.9% saline) as Dose 2 on Day 85 in a blinded fashion.

| | |
|-----------------------|---------------|
| Reporting group title | Group 4: Ad26 |
|-----------------------|---------------|

Reporting group description:

Subjects received IM injection of Ad26.ZEBOV at a dose of 5×10^{10} vp as Dose 1 on Day 1 in a blinded fashion.

| | |
|--|------------------|
| Reporting group title | Group 4: Placebo |
| Reporting group description: | |
| Subjects received Placebo (0.9% saline) as Dose 1 on Day 1 in a blinded fashion. | |

| Serious adverse events | Group 1: Cohort I: Ad26.ZEBOV then MVA-BN-Filo, 28-Day Interval | Group 2: Cohort I: Ad26.ZEBOV then MVA-BN-Filo, 56-Day Interval | Group 3: Cohort I: Ad26.ZEBOV then MVA-BN-Filo, 84-Day Interval |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 10 (10.00%) | 0 / 10 (0.00%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Osteosarcoma | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 0 / 10 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Breast Cancer | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 0 / 10 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| Human Papilloma Virus Test Positive | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 0 / 10 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Surgical and medical procedures | | | |
| Appendectomy | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 0 / 10 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Miller Fisher Syndrome | | | |

| | | | |
|---|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 0 / 10 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Small Fibre Neuropathy | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 0 / 10 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebral Venous Thrombosis | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 0 / 10 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pregnancy, puerperium and perinatal conditions | | | |
| Abortion Spontaneous | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 0 / 10 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Immune system disorders | | | |
| Food Allergy | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 0 / 10 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Inguinal Hernia | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 0 / 10 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemorrhoids | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 0 / 10 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Cholecystitis Acute | | | |

| | | | |
|---|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 10 (10.00%) | 0 / 10 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Cellulitis | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 0 / 10 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chronic Sinusitis | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 0 / 10 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatitis A | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 0 / 10 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | Group1:Cohorts II & III:Ad26.ZEBOV/MV A-BN-Filo,28-Day Interval | Group 1: Cohorts II & III: Placebo, Placebo, 28-Day Interval | Group2:Cohorts II & III:Ad26.ZEBOV/MV A-BN-Filo,56-Day Interval |
|---|---|--|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 2 / 112 (1.79%) | 0 / 13 (0.00%) | 4 / 114 (3.51%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Osteosarcoma | | | |
| subjects affected / exposed | 0 / 112 (0.00%) | 0 / 13 (0.00%) | 0 / 114 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Breast Cancer | | | |
| subjects affected / exposed | 1 / 112 (0.89%) | 0 / 13 (0.00%) | 0 / 114 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| Human Papilloma Virus Test Positive | | | |

| | | | |
|---|-----------------|----------------|-----------------|
| subjects affected / exposed | 0 / 112 (0.00%) | 0 / 13 (0.00%) | 0 / 114 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Surgical and medical procedures | | | |
| Appendectomy | | | |
| subjects affected / exposed | 0 / 112 (0.00%) | 0 / 13 (0.00%) | 1 / 114 (0.88%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Miller Fisher Syndrome | | | |
| subjects affected / exposed | 0 / 112 (0.00%) | 0 / 13 (0.00%) | 1 / 114 (0.88%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Small Fibre Neuropathy | | | |
| subjects affected / exposed | 0 / 112 (0.00%) | 0 / 13 (0.00%) | 0 / 114 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebral Venous Thrombosis | | | |
| subjects affected / exposed | 0 / 112 (0.00%) | 0 / 13 (0.00%) | 0 / 114 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pregnancy, puerperium and perinatal conditions | | | |
| Abortion Spontaneous | | | |
| subjects affected / exposed | 0 / 112 (0.00%) | 0 / 13 (0.00%) | 1 / 114 (0.88%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Immune system disorders | | | |
| Food Allergy | | | |
| subjects affected / exposed | 0 / 112 (0.00%) | 0 / 13 (0.00%) | 0 / 114 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Inguinal Hernia | | | |

| | | | |
|---|-----------------|----------------|-----------------|
| subjects affected / exposed | 0 / 112 (0.00%) | 0 / 13 (0.00%) | 0 / 114 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemorrhoids | | | |
| subjects affected / exposed | 0 / 112 (0.00%) | 0 / 13 (0.00%) | 0 / 114 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Cholecystitis Acute | | | |
| subjects affected / exposed | 0 / 112 (0.00%) | 0 / 13 (0.00%) | 0 / 114 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Cellulitis | | | |
| subjects affected / exposed | 0 / 112 (0.00%) | 0 / 13 (0.00%) | 0 / 114 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chronic Sinusitis | | | |
| subjects affected / exposed | 1 / 112 (0.89%) | 0 / 13 (0.00%) | 0 / 114 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatitis A | | | |
| subjects affected / exposed | 0 / 112 (0.00%) | 0 / 13 (0.00%) | 1 / 114 (0.88%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | Group 2: Cohorts II & III: Placebo, Placebo, 56-Day Interval | Group3:Cohorts II & III:Ad26.ZEBOV/MV A-BN-Filo,84-Day Interval | Group 3: Cohorts II & III: Placebo, Placebo, 84-Day Interval |
|---|--|---|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 1 / 13 (7.69%) | 5 / 106 (4.72%) | 1 / 18 (5.56%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Osteosarcoma | | | |

| | | | |
|---|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 106 (0.00%) | 1 / 18 (5.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Breast Cancer | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 106 (0.00%) | 0 / 18 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| Human Papilloma Virus Test Positive | | | |
| subjects affected / exposed | 1 / 13 (7.69%) | 0 / 106 (0.00%) | 0 / 18 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Surgical and medical procedures | | | |
| Appendectomy | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 106 (0.00%) | 0 / 18 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Miller Fisher Syndrome | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 106 (0.00%) | 0 / 18 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Small Fibre Neuropathy | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 106 (0.00%) | 0 / 18 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebral Venous Thrombosis | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 1 / 106 (0.94%) | 0 / 18 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pregnancy, puerperium and perinatal conditions | | | |
| Abortion Spontaneous | | | |

| | | | |
|---|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 13 (0.00%) | 1 / 106 (0.94%) | 0 / 18 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Immune system disorders | | | |
| Food Allergy | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 1 / 106 (0.94%) | 0 / 18 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Inguinal Hernia | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 1 / 106 (0.94%) | 0 / 18 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemorrhoids | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 106 (0.00%) | 0 / 18 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Cholecystitis Acute | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 106 (0.00%) | 0 / 18 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Cellulitis | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 1 / 106 (0.94%) | 0 / 18 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chronic Sinusitis | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 106 (0.00%) | 0 / 18 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatitis A | | | |

| | | | |
|---|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 106 (0.00%) | 0 / 18 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | Group 4: Ad26 | Group 4: Placebo | |
|---|-----------------|------------------|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 2 / 13 (15.38%) | 0 / 2 (0.00%) | |
| number of deaths (all causes) | 0 | 0 | |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Osteosarcoma | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Breast Cancer | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Investigations | | | |
| Human Papilloma Virus Test Positive | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Surgical and medical procedures | | | |
| Appendicectomy | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nervous system disorders | | | |
| Miller Fisher Syndrome | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Small Fibre Neuropathy | | | |

| | | | |
|---|----------------|---------------|--|
| subjects affected / exposed | 1 / 13 (7.69%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cerebral Venous Thrombosis | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pregnancy, puerperium and perinatal conditions | | | |
| Abortion Spontaneous | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Immune system disorders | | | |
| Food Allergy | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal disorders | | | |
| Inguinal Hernia | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haemorrhoids | | | |
| subjects affected / exposed | 1 / 13 (7.69%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatobiliary disorders | | | |
| Cholecystitis Acute | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infections and infestations | | | |
| Cellulitis | | | |

| | | | |
|---|----------------|---------------|--|
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chronic Sinusitis | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatitis A | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 2 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | Group 1:Cohort I:Ad26.ZEBOV then MVA-BN-Filo,28-Day Interval | Group 2:Cohort I: Ad26.ZEBOV then MVA-BN-Filo, 56-Day Interval | Group 3:Cohort I: Ad26.ZEBOV then MVA-BN-Filo, 84-Day Interval |
|---|--|--|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 4 / 10 (40.00%) | 5 / 10 (50.00%) | 6 / 10 (60.00%) |
| Investigations | | | |
| Alanine Aminotransferase Increased | | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 1 / 10 (10.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Aspartate Aminotransferase Increased | | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 1 / 10 (10.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Blood Creatinine Increased | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 10 (10.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Neutrophil Count Decreased | | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 1 / 10 (10.00%) | 2 / 10 (20.00%) |
| occurrences (all) | 1 | 1 | 3 |
| Prothrombin Time Prolonged | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|--|----------------|-----------------|-----------------|
| Injury, poisoning and procedural complications | | | |
| Ligament Sprain | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nervous system disorders | | | |
| Dizziness Postural | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 10 (10.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Dysgeusia | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Headache | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| General disorders and administration site conditions | | | |
| Application Site Bruise | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Asthenia | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Influenza Like Illness | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Injection Site Erythema | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Injection Site Pain | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear and labyrinth disorders | | | |
| Vertigo | | | |

| | | | |
|--|---------------------|---------------------|---------------------|
| subjects affected / exposed occurrences (all) | 0 / 10 (0.00%) 0 | 0 / 10 (0.00%) 0 | 0 / 10 (0.00%) 0 |
| Gastrointestinal disorders | | | |
| Dental Discomfort | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nausea | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 2 / 10 (20.00%) |
| occurrences (all) | 0 | 0 | 2 |
| Odynophagia | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral Pain | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Toothache | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Vomiting | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Asthma | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Cough | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rhinorrhoea | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin and subcutaneous tissue disorders | | | |

| | | | |
|---|----------------|-----------------|-----------------|
| Eczema | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pruritus | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 10 (10.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Urticaria | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 10 (10.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Back Pain | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 10 (10.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Chondropathy | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal Pain | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Osteoarthritis | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pain in Extremity | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Infections and infestations | | | |
| Cellulitis | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 10 (10.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Conjunctivitis | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasopharyngitis | | | |

| | | | |
|-----------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pharyngitis | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rhinitis | | | |
| subjects affected / exposed | 1 / 10 (10.00%) | 1 / 10 (10.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 1 | 1 | 1 |
| Tooth Abscess | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 1 / 10 (10.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Upper Respiratory Tract Infection | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Urinary Tract Infection | | | |
| subjects affected / exposed | 0 / 10 (0.00%) | 0 / 10 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| Non-serious adverse events | Group1:Cohorts II & III:Ad26.ZEBOV/MV A-BN-Filo,28-Day Interval | Group 1: Cohorts II & III: Placebo, Placebo, 28-Day Interval | Group2:Cohorts II & III:Ad26.ZEBOV/MV A-BN-Filo,56-Day Interval |
|---|---|--|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 41 / 112 (36.61%) | 6 / 13 (46.15%) | 30 / 114 (26.32%) |
| Investigations | | | |
| Alanine Aminotransferase Increased | | | |
| subjects affected / exposed | 0 / 112 (0.00%) | 0 / 13 (0.00%) | 1 / 114 (0.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Aspartate Aminotransferase Increased | | | |
| subjects affected / exposed | 0 / 112 (0.00%) | 0 / 13 (0.00%) | 3 / 114 (2.63%) |
| occurrences (all) | 0 | 0 | 3 |
| Blood Creatinine Increased | | | |
| subjects affected / exposed | 1 / 112 (0.89%) | 0 / 13 (0.00%) | 0 / 114 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Neutrophil Count Decreased | | | |
| subjects affected / exposed | 3 / 112 (2.68%) | 0 / 13 (0.00%) | 2 / 114 (1.75%) |
| occurrences (all) | 3 | 0 | 2 |
| Prothrombin Time Prolonged | | | |

| | | | |
|---|----------------------|---------------------|----------------------|
| subjects affected / exposed occurrences (all) | 1 / 112 (0.89%) 1 | 0 / 13 (0.00%) 0 | 1 / 114 (0.88%) 1 |
| Injury, poisoning and procedural complications Ligament Sprain subjects affected / exposed occurrences (all) | 1 / 112 (0.89%) 2 | 1 / 13 (7.69%) 1 | 0 / 114 (0.00%) 0 |
| Nervous system disorders Dizziness Postural subjects affected / exposed occurrences (all) | 1 / 112 (0.89%) 1 | 0 / 13 (0.00%) 0 | 0 / 114 (0.00%) 0 |
| Dysgeusia subjects affected / exposed occurrences (all) | 0 / 112 (0.00%) 0 | 0 / 13 (0.00%) 0 | 0 / 114 (0.00%) 0 |
| Headache subjects affected / exposed occurrences (all) | 3 / 112 (2.68%) 3 | 1 / 13 (7.69%) 1 | 3 / 114 (2.63%) 3 |
| General disorders and administration site conditions Application Site Bruise subjects affected / exposed occurrences (all) | 0 / 112 (0.00%) 0 | 0 / 13 (0.00%) 0 | 0 / 114 (0.00%) 0 |
| Asthenia subjects affected / exposed occurrences (all) | 0 / 112 (0.00%) 0 | 0 / 13 (0.00%) 0 | 1 / 114 (0.88%) 1 |
| Influenza Like Illness subjects affected / exposed occurrences (all) | 2 / 112 (1.79%) 2 | 0 / 13 (0.00%) 0 | 2 / 114 (1.75%) 2 |
| Injection Site Erythema subjects affected / exposed occurrences (all) | 1 / 112 (0.89%) 1 | 0 / 13 (0.00%) 0 | 0 / 114 (0.00%) 0 |
| Injection Site Pain subjects affected / exposed occurrences (all) | 0 / 112 (0.00%) 0 | 0 / 13 (0.00%) 0 | 0 / 114 (0.00%) 0 |
| Pyrexia subjects affected / exposed occurrences (all) | 0 / 112 (0.00%) 0 | 0 / 13 (0.00%) 0 | 0 / 114 (0.00%) 0 |
| Ear and labyrinth disorders | | | |

| | | | |
|---|----------------------|---------------------|----------------------|
| Vertigo subjects affected / exposed occurrences (all) | 0 / 112 (0.00%) 0 | 1 / 13 (7.69%) 1 | 1 / 114 (0.88%) 1 |
| Gastrointestinal disorders | | | |
| Dental Discomfort subjects affected / exposed occurrences (all) | 0 / 112 (0.00%) 0 | 0 / 13 (0.00%) 0 | 1 / 114 (0.88%) 1 |
| Diarrhoea subjects affected / exposed occurrences (all) | 0 / 112 (0.00%) 0 | 0 / 13 (0.00%) 0 | 1 / 114 (0.88%) 1 |
| Nausea subjects affected / exposed occurrences (all) | 0 / 112 (0.00%) 0 | 0 / 13 (0.00%) 0 | 2 / 114 (1.75%) 2 |
| Odynophagia subjects affected / exposed occurrences (all) | 0 / 112 (0.00%) 0 | 0 / 13 (0.00%) 0 | 0 / 114 (0.00%) 0 |
| Oral Pain subjects affected / exposed occurrences (all) | 0 / 112 (0.00%) 0 | 0 / 13 (0.00%) 0 | 0 / 114 (0.00%) 0 |
| Toothache subjects affected / exposed occurrences (all) | 0 / 112 (0.00%) 0 | 0 / 13 (0.00%) 0 | 0 / 114 (0.00%) 0 |
| Vomiting subjects affected / exposed occurrences (all) | 0 / 112 (0.00%) 0 | 0 / 13 (0.00%) 0 | 0 / 114 (0.00%) 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Asthma subjects affected / exposed occurrences (all) | 0 / 112 (0.00%) 0 | 0 / 13 (0.00%) 0 | 0 / 114 (0.00%) 0 |
| Cough subjects affected / exposed occurrences (all) | 2 / 112 (1.79%) 2 | 0 / 13 (0.00%) 0 | 2 / 114 (1.75%) 2 |
| Rhinorrhoea subjects affected / exposed occurrences (all) | 4 / 112 (3.57%) 4 | 0 / 13 (0.00%) 0 | 1 / 114 (0.88%) 1 |
| Skin and subcutaneous tissue disorders | | | |

| | | | |
|---|-----------------|----------------|-----------------|
| Eczema | | | |
| subjects affected / exposed | 0 / 112 (0.00%) | 0 / 13 (0.00%) | 0 / 114 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pruritus | | | |
| subjects affected / exposed | 1 / 112 (0.89%) | 0 / 13 (0.00%) | 0 / 114 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Urticaria | | | |
| subjects affected / exposed | 0 / 112 (0.00%) | 0 / 13 (0.00%) | 0 / 114 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 1 / 112 (0.89%) | 0 / 13 (0.00%) | 1 / 114 (0.88%) |
| occurrences (all) | 1 | 0 | 1 |
| Back Pain | | | |
| subjects affected / exposed | 3 / 112 (2.68%) | 0 / 13 (0.00%) | 1 / 114 (0.88%) |
| occurrences (all) | 4 | 0 | 2 |
| Chondropathy | | | |
| subjects affected / exposed | 0 / 112 (0.00%) | 0 / 13 (0.00%) | 0 / 114 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal Pain | | | |
| subjects affected / exposed | 2 / 112 (1.79%) | 0 / 13 (0.00%) | 0 / 114 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Osteoarthritis | | | |
| subjects affected / exposed | 0 / 112 (0.00%) | 0 / 13 (0.00%) | 0 / 114 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pain in Extremity | | | |
| subjects affected / exposed | 1 / 112 (0.89%) | 0 / 13 (0.00%) | 1 / 114 (0.88%) |
| occurrences (all) | 1 | 0 | 1 |
| Infections and infestations | | | |
| Cellulitis | | | |
| subjects affected / exposed | 0 / 112 (0.00%) | 0 / 13 (0.00%) | 0 / 114 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Conjunctivitis | | | |
| subjects affected / exposed | 0 / 112 (0.00%) | 1 / 13 (7.69%) | 0 / 114 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Nasopharyngitis | | | |

| | | | |
|-----------------------------------|-----------------|----------------|-----------------|
| subjects affected / exposed | 3 / 112 (2.68%) | 0 / 13 (0.00%) | 0 / 114 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Pharyngitis | | | |
| subjects affected / exposed | 2 / 112 (1.79%) | 0 / 13 (0.00%) | 0 / 114 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Rhinitis | | | |
| subjects affected / exposed | 7 / 112 (6.25%) | 0 / 13 (0.00%) | 6 / 114 (5.26%) |
| occurrences (all) | 8 | 0 | 6 |
| Tooth Abscess | | | |
| subjects affected / exposed | 0 / 112 (0.00%) | 0 / 13 (0.00%) | 1 / 114 (0.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Upper Respiratory Tract Infection | | | |
| subjects affected / exposed | 6 / 112 (5.36%) | 1 / 13 (7.69%) | 6 / 114 (5.26%) |
| occurrences (all) | 7 | 1 | 6 |
| Urinary Tract Infection | | | |
| subjects affected / exposed | 1 / 112 (0.89%) | 1 / 13 (7.69%) | 0 / 114 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |

| Non-serious adverse events | Group 2: Cohorts II & III: Placebo, Placebo, 56-Day Interval | Group3:Cohorts II & III:Ad26.ZEBOV/MV A-BN-Filo,84-Day Interval | Group 3: Cohorts II & III: Placebo, Placebo, 84-Day Interval |
|---|--|---|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 7 / 13 (53.85%) | 26 / 106 (24.53%) | 8 / 18 (44.44%) |
| Investigations | | | |
| Alanine Aminotransferase Increased | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 3 / 106 (2.83%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Aspartate Aminotransferase Increased | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 3 / 106 (2.83%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Blood Creatinine Increased | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 106 (0.00%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil Count Decreased | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 2 / 106 (1.89%) | 1 / 18 (5.56%) |
| occurrences (all) | 0 | 2 | 1 |
| Prothrombin Time Prolonged | | | |

| | | | |
|--|--|--|--|
| subjects affected / exposed occurrences (all) | 1 / 13 (7.69%) 1 | 0 / 106 (0.00%) 0 | 0 / 18 (0.00%) 0 |
| Injury, poisoning and procedural complications Ligament Sprain subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 106 (0.00%) 0 | 0 / 18 (0.00%) 0 |
| Nervous system disorders Dizziness Postural subjects affected / exposed occurrences (all) Dysgeusia subjects affected / exposed occurrences (all) Headache subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 0 / 13 (0.00%) 0 1 / 13 (7.69%) 1 | 1 / 106 (0.94%) 1 1 / 106 (0.94%) 1 5 / 106 (4.72%) 12 | 0 / 18 (0.00%) 0 1 / 18 (5.56%) 1 0 / 18 (0.00%) 0 |
| General disorders and administration site conditions Application Site Bruise subjects affected / exposed occurrences (all) Asthenia subjects affected / exposed occurrences (all) Influenza Like Illness subjects affected / exposed occurrences (all) Injection Site Erythema subjects affected / exposed occurrences (all) Injection Site Pain subjects affected / exposed occurrences (all) Pyrexia subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 0 / 13 (0.00%) 0 0 / 13 (0.00%) 0 0 / 13 (0.00%) 0 0 / 13 (0.00%) 0 0 / 13 (0.00%) 0 | 0 / 106 (0.00%) 0 0 / 106 (0.00%) 0 0 / 106 (0.00%) 0 0 / 106 (0.00%) 0 0 / 106 (0.00%) 0 | 1 / 18 (5.56%) 1 1 / 18 (5.56%) 1 0 / 18 (0.00%) 0 0 / 18 (0.00%) 0 0 / 18 (0.00%) 0 1 / 18 (5.56%) 1 |
| Ear and labyrinth disorders | | | |

| | | | |
|---|----------------------|----------------------|---------------------|
| Vertigo subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 106 (0.00%) 0 | 0 / 18 (0.00%) 0 |
| Gastrointestinal disorders | | | |
| Dental Discomfort subjects affected / exposed occurrences (all) | 1 / 13 (7.69%) 1 | 0 / 106 (0.00%) 0 | 0 / 18 (0.00%) 0 |
| Diarrhoea subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 1 / 106 (0.94%) 1 | 1 / 18 (5.56%) 1 |
| Nausea subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 106 (0.00%) 0 | 0 / 18 (0.00%) 0 |
| Odynophagia subjects affected / exposed occurrences (all) | 1 / 13 (7.69%) 1 | 0 / 106 (0.00%) 0 | 0 / 18 (0.00%) 0 |
| Oral Pain subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 106 (0.00%) 0 | 1 / 18 (5.56%) 1 |
| Toothache subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 1 / 106 (0.94%) 1 | 1 / 18 (5.56%) 1 |
| Vomiting subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 106 (0.00%) 0 | 0 / 18 (0.00%) 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Asthma subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 106 (0.00%) 0 | 0 / 18 (0.00%) 0 |
| Cough subjects affected / exposed occurrences (all) | 1 / 13 (7.69%) 1 | 0 / 106 (0.00%) 0 | 0 / 18 (0.00%) 0 |
| Rhinorrhoea subjects affected / exposed occurrences (all) | 2 / 13 (15.38%) 2 | 3 / 106 (2.83%) 3 | 0 / 18 (0.00%) 0 |
| Skin and subcutaneous tissue disorders | | | |

| | | | |
|---|----------------|-----------------|----------------|
| Eczema | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 106 (0.00%) | 1 / 18 (5.56%) |
| occurrences (all) | 0 | 0 | 1 |
| Pruritus | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 106 (0.00%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urticaria | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 106 (0.00%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 1 / 13 (7.69%) | 0 / 106 (0.00%) | 1 / 18 (5.56%) |
| occurrences (all) | 1 | 0 | 1 |
| Back Pain | | | |
| subjects affected / exposed | 1 / 13 (7.69%) | 3 / 106 (2.83%) | 0 / 18 (0.00%) |
| occurrences (all) | 1 | 3 | 0 |
| Chondropathy | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 106 (0.00%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal Pain | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 106 (0.00%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Osteoarthritis | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 106 (0.00%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pain in Extremity | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 106 (0.00%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infections and infestations | | | |
| Cellulitis | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 106 (0.00%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Conjunctivitis | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 106 (0.00%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasopharyngitis | | | |

| | | | |
|-----------------------------------|----------------|-----------------|----------------|
| subjects affected / exposed | 1 / 13 (7.69%) | 1 / 106 (0.94%) | 0 / 18 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Pharyngitis | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 106 (0.00%) | 1 / 18 (5.56%) |
| occurrences (all) | 0 | 0 | 1 |
| Rhinitis | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 3 / 106 (2.83%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Tooth Abscess | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 106 (0.00%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper Respiratory Tract Infection | | | |
| subjects affected / exposed | 1 / 13 (7.69%) | 3 / 106 (2.83%) | 1 / 18 (5.56%) |
| occurrences (all) | 1 | 3 | 1 |
| Urinary Tract Infection | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 106 (0.00%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| Non-serious adverse events | Group 4: Ad26 | Group 4: Placebo | |
|---|-----------------|------------------|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 6 / 13 (46.15%) | 1 / 2 (50.00%) | |
| Investigations | | | |
| Alanine Aminotransferase Increased | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Aspartate Aminotransferase Increased | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Blood Creatinine Increased | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Neutrophil Count Decreased | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Prothrombin Time Prolonged | | | |

| | | | |
|--|--|--|--|
| subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Injury, poisoning and procedural complications Ligament Sprain subjects affected / exposed occurrences (all) | 1 / 13 (7.69%) 1 | 0 / 2 (0.00%) 0 | |
| Nervous system disorders Dizziness Postural subjects affected / exposed occurrences (all) Dysgeusia subjects affected / exposed occurrences (all) Headache subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 0 / 13 (0.00%) 0 0 / 13 (0.00%) 0 | 0 / 2 (0.00%) 0 0 / 2 (0.00%) 0 0 / 2 (0.00%) 0 | |
| General disorders and administration site conditions Application Site Bruise subjects affected / exposed occurrences (all) Asthenia subjects affected / exposed occurrences (all) Influenza Like Illness subjects affected / exposed occurrences (all) Injection Site Erythema subjects affected / exposed occurrences (all) Injection Site Pain subjects affected / exposed occurrences (all) Pyrexia subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 0 / 13 (0.00%) 0 1 / 13 (7.69%) 1 0 / 13 (0.00%) 0 0 / 13 (0.00%) 0 0 / 13 (0.00%) 0 | 0 / 2 (0.00%) 0 0 / 2 (0.00%) 0 0 / 2 (0.00%) 0 0 / 2 (0.00%) 0 0 / 2 (0.00%) 0 | |
| Ear and labyrinth disorders | | | |

| | | | |
|---|---------------------|--------------------|--|
| Vertigo subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Gastrointestinal disorders | | | |
| Dental Discomfort subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Diarrhoea subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Nausea subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Odynophagia subjects affected / exposed occurrences (all) | 1 / 13 (7.69%) 1 | 0 / 2 (0.00%) 0 | |
| Oral Pain subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Toothache subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Vomiting subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Asthma subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Cough subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Rhinorrhoea subjects affected / exposed occurrences (all) | 0 / 13 (0.00%) 0 | 0 / 2 (0.00%) 0 | |
| Skin and subcutaneous tissue disorders | | | |

| | | | |
|---|-----------------|----------------|--|
| Eczema | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Pruritus | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Urticaria | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Back Pain | | | |
| subjects affected / exposed | 2 / 13 (15.38%) | 0 / 2 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Chondropathy | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 1 / 2 (50.00%) | |
| occurrences (all) | 0 | 1 | |
| Musculoskeletal Pain | | | |
| subjects affected / exposed | 1 / 13 (7.69%) | 0 / 2 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Osteoarthritis | | | |
| subjects affected / exposed | 1 / 13 (7.69%) | 0 / 2 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Pain in Extremity | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Infections and infestations | | | |
| Cellulitis | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Conjunctivitis | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Nasopharyngitis | | | |

| | | | |
|-----------------------------------|----------------|---------------|--|
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Pharyngitis | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Rhinitis | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Tooth Abscess | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Upper Respiratory Tract Infection | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Urinary Tract Infection | | | |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 2 (0.00%) | |
| occurrences (all) | 0 | 0 | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|-------------------|--|
| 07 May 2015 | This amendment was created upon request of the Medicines and Healthcare Products Regulatory Agency (MHRA). Further modifications were made to implement a site-specific request, to update the list of references and to correct minor inconsistencies. |
| 18 August 2015 | This amendment was created to implement site-specific requests and only subjects who received active vaccine were entered a long-term follow-up phase. |
| 26 January 2016 | This amendment includes the request of the Center for Biologics Evaluation and Research (CBER, a division of US Food and Drug Administration [FDA]) to extend the safety follow-up to 6 months post-dose 2. |
| 01 September 2016 | The sponsor halted vaccinations following a case of Miller Fisher syndrome after receipt of MVA-BN-Filo or placebo in this clinical study, until a revised informed consent form (ICF) containing updated safety language for the current study VAC52150EBL2001 was prepared and approval to restart the study was granted by the relevant competent authority. As a result of the pause, some subjects were outside the protocol-defined dose 2 vaccination window. Information was added to clarify the procedures that need to be followed for these subjects. As requested by the Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM), wording on the collection of Immediate Reportable Events was added after observation of the case of Miller Fisher syndrome. Randomization to Group 3 was stopped to focus on the schedules for which an indication was sought. |
| 20 April 2017 | This amendment was created due to significant delays in scheduled dose 2 vaccinations caused by study pauses required for safety evaluations. Since many subjects in France have had no dose 2 vaccination and many subjects in the United Kingdom (UK) have had a late dose 2 vaccination, it was very difficult to evaluate the planned dosing regimens. Therefore, no further subjects were recruited in the entire study (ie, UK and France). Vaccinated subjects in both countries were followed per protocol for safety. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? Yes

| Date | Interruption | Restart date |
|---------------|--|--------------|
| 27 April 2016 | Study vaccinations were halted due to the occurrence of a serious adverse event (Miller Fisher syndrome). The event was considered to be possibly related to study vaccination by the investigator and therefore met the pre-specified pausing rules installed for this study. Per IDMC recommendation, further investigations and analyses were performed, and all study vaccinations were halted until the safety language of the ICF was updated. | 27 May 2016 |

| | | |
|-------------|--|-------------------|
| 20 May 2016 | A second serious adverse event was reported (initially reported as 'possible cervical myelitis', ultimately diagnosed as small fiber neuropathy), which also was assessed as possibly related to study vaccination by the investigator and investigated and analyzed further. This event resulted in halt of screening and all study vaccinations. | 27 September 2016 |
|-------------|--|-------------------|

Notes:

Limitations and caveats

None reported